“Hepatocellular carcinoma: A life-threatening disease”

Biomedicine and Pharmacotherapy

Volumn 84, Issue , 2016, Pages 1679-1688

  Chacko, Shinu ^a   Samanta, Subir ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY   (India)

Author keywords

Hepatocellular carcinoma; Immunotherapy; Molecular targeted therapy; Peptide hybrid; Personalized medicine; Transarterial chemoembolization

Indexed keywords

ANTINEOPLASTIC AGENT; CHECKPOINT KINASE 1; IMMUNOMODULATING AGENT; MOLECULAR THERAPY AGENT; VASCULOTROPIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTERIAL EMBOLIZATION; CANCER EPIDEMIOLOGY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER RISK; CANCER SURGERY; DRUG TARGETING; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; MOLECULARLY TARGETED THERAPY; PERCUTANEOUS ABLATION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; TUMOR ABLATION; ANIMAL; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; IMMUNOTHERAPY; LIVER NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY;

EID: 85001969730     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.10.078     Document Type: Review

References (53)

1. [1] Craig, C.R., Stitzel, R.E., Modern Pharmacology with Clinical Applications. 5th ed., 2004, Lippincott Williams & Wilkins.
2. [2] Globocan, Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. 2012, Globocan (Accessed 31 August 2016).
3. [3] Alisi, A., Balsano, C., Enhancing the efficacy of hepatocellular carcinoma chemotherapeutics with natural anticancer agents. Nutr. Rev. 65:12 (2007), 550–553.
4. [4] Velázquez, R.F., Rodriguez, M., Navascues, C.A., Linares, A., Perez, R., Sotorríos, N.G., Martinez, I., Rodrigo, L., Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 37:3 (2003), 520–527.
5. [5] Acharya, S.K., Epidemiology of hepatocellular carcinoma in India. J. Clin. Exp. Hepatol. 4:Suppl. 3 (2014), S27–33.
6. [6] El-Serag, H.B., Hepatocellular carcinoma. N. Engl. J. Med. 365:12 (2011), 1118–1127.
7. [7] Fattovich, G., Stroffolini, T., Zagni, I., Donato, F., Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127:5 (2004), S35–S50.
8. [8] Donato, F., Tagger, A., Gelatti, U., Parrinello, G., Boffetta, P., Albertini, A., Decarli, A., Trevisi, P., Ribero, M.L., Martelli, C., Porru, S., Nardi, G., Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am. J. Epidemiol. 155:4 (2002), 323–331.
9. [9] Neuschwander-Tetri, B.A., Caldwell, S.H., Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 37:5 (2003), 1202–1219.
10. [10] Chacko, S., Samanta, S., Novel thiosemicarbazide hybrids with amino acids and peptides against hepatocellular carcinoma: a molecular designing approach towards multikinase inhibitor. Curr. Comp.-Aided Drug Des. 11:3 (2015), 279–290.
11. [11] Farazi, P.A., DePinho, R.A., Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 6:9 (2006), 674–687.
12. [12] Gaetano, B., Shirin, D., Nicoletta, B., Ardiri, A., Management of hepatocellular carcinoma: an update at the start of 2014. J. Gastrointest. Dig. Syst., 04(02), 2014.
13. [13] Ryerson, A.B., Eheman, C.R., Altekruse, S.F., Ward, J.W., Jemal, A., Sherman, R.L., Henley, S.J., Holtzman, D., Lake, A., Noone, A.M., Annual Report to the Nation on the Status of Cancer, 1975‐2012, featuring the increasing incidence of liver cancer. Cancer 122:9 (2016), 1312–1337.
14. [14] Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA: Cancer J. Clin. 66:1 (2016), 7–30.
15. [15] Hashim, D., Boffetta, P., La Vecchia, C., Rota, M., Bertuccio, P., Malvezzi, M., Negri, E., The global decrease in cancer mortality: trends and disparities. Ann. Oncol. 27:5 (2016), 926–933.
16. [16] Bosetti, C., Levi, F., Boffetta, P., Lucchini, F., Negri, E., La Vecchia, C., Trends in mortality from hepatocellular carcinoma in Europe 1980–2004. Hepatology 48:1 (2008), 137–145.
17. [17] About national cancer registry programme. http://www.ncrpindia.org/About_NCRP.aspx, 2016 (Accessed 01 September 2016).
18. [18] National cancer registry programme: Three-year report of population based cancer registries 2012–2014. http://ncrpindia.org/Annual_Reports.aspx, 2016 (Accessed 01 September 2016).
19. [19] Pons, F., Varela, M., Llovet, J.M., Staging systems in hepatocellular carcinoma. HPB: Off. J. Int. Hepato Pancreato Biliary Assoc. 7:1 (2005), 35–41.
20. [20] Llovet, J.M., Burroughs, A., Bruix, J., Hepatocellular carcinoma. Lancet 362:9399 (2003), 1907–1917.
21. [21] Mazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., Gennari, L., Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 334:11 (1996), 693–699.
22. [22] Bruix, J., Llovet, J.M., Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35:3 (2002), 519–524.
23. [23] Raza, A., Sood, G.K., Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J. Gastroenterol.: WJG 20:15 (2014), 4115–4127.
24. [24] Shiina, S., Japanese experience in ablation therapies for hepatocellular carcinoma. Hepatol. Res., 37(s2), 2007.
25. [25] Crocetti, L., Lencioni, R., Thermal ablation of hepatocellular carcinoma. Cancer Imaging 8 (2008), 19–26.
26. [26] Livraghi, T., Goldberg, S.N., Lazzaroni, S., Meloni, F., Solbiati, L., Gazelle, G.S., Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 210:3 (1999), 655–661.
27. [27] Kawai, S., Okamura, J., Ogawa, M., Ohashi, Y., Tani, M., Inoue, J., Kawarada, Y., Kusano, M., Kubo, Y., Kuroda, C., Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma—a comparison of lipiodol-transcatheter arterial embolization with and without Adriamycin (first cooperative study). Cancer Chemother. Pharmacol. 31:1 (1992), S1–S6.
28. [28] Llovet, J.M., Bruix, J., Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:2 (2003), 429–442.
29. [29] Song, M.J., Chun, H.J., Song, D.S., Kim, H.Y., Yoo, S.H., Park, C.H., Bae, S.H., Choi, J.Y., Chang, U.I., Yang, J.M., Lee, H.G., Yoon, S.K., Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J. Hepatol. 57:6 (2012), 1244–1250.
30. [30] Lau, W.Y., Sangro, B., Chen, P.J., Cheng, S.Q., Chow, P., Lee, R.C., Leung, T., Han, K.H., Poon, R.T., Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90. Oncology 84:5 (2013), 311–318.
31. [31] Salem, R., Lewandowski, R.J., Kulik, L., Wang, E., Riaz, A., Ryu, R.K., Sato, K.T., Gupta, R., Nikolaidis, P., Miller, F.H., Yaghmai, V., Ibrahim, S.M., Senthilnathan, S., Baker, T., Gates, V.L., Atassi, B., Newman, S., Memon, K., Chen, R., Vogelzang, R.L., Nemcek, A.A., Resnick, S.A., Chrisman, H.B., Carr, J., Omary, R.A., Abecassis, M., Benson, A.B. 3rd, Mulcahy, M.F., Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140:2 (2011), 497–507 (e2).
32. [32] Sangro, B., Inarrairaegui, M., Bilbao, J.I., Radioembolization for hepatocellular carcinoma. J. Hepatol. 56:2 (2012), 464–473.
33. [33] Pardee, A.D., Butterfield, L.H., Immunotherapy of hepatocellular carcinoma: unique challenges and clinical opportunities. Oncoimmunology 1:1 (2012), 48–55.
34. [34] Hong, Y.-P., Li, Z.-D., Prasoon, P., Zhang, Q., Immunotherapy for hepatocellular carcinoma: from basic research to clinical use. World J. Hepatol. 7:7 (2015), 980–992.
35. [35] Butterfield, L.H., Ribas, A., Meng, W.S., Dissette, V.B., Amarnani, S., Vu, H.T., Seja, E., Todd, K., Glaspy, J.A., McBride, W.H., T-cell responses to HLA-A* 0201 immunodominant peptides derived from α-fetoprotein in patients with hepatocellular cancer. Clin. Cancer Res. 9:16 (2003), 5902–5908.
36. [36] Komori, H., Nakatsura, T., Senju, S., Yoshitake, Y., Motomura, Y., Ikuta, Y., Fukuma, D., Yokomine, K., Harao, M., Beppu, T., Identification of HLA-A2-or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin. Cancer Res. 12:9 (2006), 2689–2697.
37. [37] Perica, K., Varela, J.C., Oelke, M., Schneck, J., Adoptive T cell immunotherapy for cancer. Rambam Maimonides Med. J., 6(1), 2015, e0004.
38. [38] JM, Llovet, S., Ricci, V., Mazzaferro, P., Hilgard, E., Gane, J.F., Blanc, A.C., de Oliveira, A., Santoro, J.L., Raoul, A., Forner, M., Schwartz, C., Porta, S., Zeuzem, L., Bolondi, T.F., Greten, P.R., Galle, J.F., Seitz, I., Borbath, D., Haussinger, T., Giannaris, M., Shan, M., Moscovici, D., Voliotis, Bruix, J., S.I.S. Group, Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359:4 (2008), 378–390.
39. [39] Pipa-Muniz, M., Varela, M., Gonzalez-Dieguez, L., Rodríguez, M., Personalized medicine in hepatocellular carcinoma: rationale and clinical data. Clin. Investig. 1:10 (2011), 1403–1411.
40. [40] Cabrera, R., Pannu, D.S., Caridi, J., Firpi, R.J., Soldevila-Pico, C., Morelli, G., Clark, V., Suman, A., George, T.J. Jr., Nelson, D.R., The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. Aliment. Pharmacol. Ther. 34:2 (2011), 205–213.
41. [41] Gadani, S., Mahvash, A., Avritscher, R., Chasen, B., Kaseb, A., Murthy, R., Yttirum-90 resin microspheres as an adjunct to sorafenib in patients with unresectable HCC: A retrospective study for evaluation of survival benefit and adverse events. Soc. Interventional Radiol. Ann. Sci. Meeting, 2013 p. Abstract 62.
42. [42] Kumar, V., Khan, S., Gupta, P., Rastogi, N., Mishra, D.P., Ahmed, S., Siddiqi, M.I., Identification of novel inhibitors of human Chk1 using pharmacophore-based virtual screening and their evaluation as potential anti-cancer agents. J. Comput. Aided. Mol. Des. 28:12 (2014), 1247–1256.
43. [43] Tanaka, S., Arii, S., Molecular targeted therapies in hepatocellular carcinoma. Semin. Oncol. 39:4 (2012), 486–492.
44. [44] Zhang, L., Wang, X., Feng, J., Jia, Y., Xu, F., Xu, W., Discovery of novel vascular endothelial growth factor receptor 2 inhibitors: a virtual screening approach. Chem. Biol. Drug Des. 80:6 (2012), 893–901.
45. [45] Xie, Y., Wei, R.-R., Huang, G.-L., Zhang, M.-Y., Yuan, Y.-F., Wang, H.-Y., Checkpoint kinase 1 is negatively regulated by miR-497 in hepatocellular carcinoma. Med. Oncol. 31:3 (2014), 1–5.
46. [46] Garrett, M.D., Collins, I., Anticancer therapy with checkpoint inhibitors: what, where and when?. Trends Pharmacol. Sci. 32:5 (2011), 308–316.
47. [47] Li, J., Tan, H., Dong, X., Xu, Z., Shi, C., Han, X., Jiang, H., Krissansen, G.W., Sun, X., Antisense integrin alphaV and beta3 gene therapy suppresses subcutaneously implanted hepatocellular carcinomas. Dig. Liver Dis. 39:6 (2007), 557–565.
48. [48] Persidis, A., Cancer multidrug resistance. Nat. Biotechnol. 17:1 (2000), 94–95.
49. [49] Li, C., Poly (L-glutamic acid)–anticancer drug conjugates. Adv. Drug. Deliv. Rev. 54:5 (2002), 695–713.
50. [50] Evindar, G., Batey, R.A., Peptide heterocycle conjugates: a diverted edman degradation protocol for the synthesis of N-terminal 2-Iminohydantoins. Org. Lett. 5:8 (2003), 1201–1204.
51. [51] Bauer, D., Sadler, P., The structure‐activity relashionship of the antiviral chemotherapeutic activity of Isatin β-thiosemicarbazone. Br. J. Pharm. Chemother. 15:1 (1960), 101–110.
52. [52] Zhang, H.-J., Qian, Y., Zhu, D.-D., Yang, X.-G., Zhu, H.-L., Synthesis, molecular modeling and biological evaluation of chalcone thiosemicarbazide derivatives as novel anticancer agents. Eur. J. Med. Chem. 46:9 (2011), 4702–4708.
53. [53] Barry, V.C., Conalty, M., O'Callaghan, C., Twomey, D., Anticancer agents: III synthesis and anticancer activity of some bisthiosemicarbazones and thiosemicarbazides. Proceedings of the Royal Irish Academy Section B: Biological, Geological, and Chemical Science, JSTOR, 1966, 309–324.